Characterization and Outcomes of Spanish Patients With Relapsed/Refractory Multiple Myeloma Included in the LocoMMotion Study
Despite treatment advances that have improved patient survival, including immunomodulatory drugs (IMiDs), proteasome inhibitors (PIs), and anti-CD38 monoclonal antibodies (mAbs), multiple myeloma (MM) remains incurable.1,2 Most patients ultimately relapse or become refractory to standard drug classes.3,4 Triple-class exposed patients with relapsed/refractory MM (RRMM) have particularly aggressive disease and a poor prognosis.5 This may, in part, be due to the increasing genetic complexity and more drug-resistant mutations that occur with each new line of therapy (LOT), particularly for patients with high-risk cytogenetics.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Maria-Victoria Mateos, Katja Weisel, Joris Diels, Alberto Arribas, Maria Tamayo, Jordan M. Schecter, Tito Roccia, Im ène Haddad, Lida Pacaud, Philippe Moreau Tags: Original Study Source Type: research
More News: Genetics | Hematology | Jordan Health | Leukemia | Lymphoma | Middle East Health | Myeloma | Spain Health | Study